About TVT 2019 Structural Heart Summit

Transcatheter valve therapy (TVT) has emerged as a growing new treatment option for patients with valvular heart disease. TVT is the featured core of the Structural Heart Disease Summit; and the landscape of TVT is rapidly evolving, with the maturation of Transcatheter Aortic Valve Replacement (TAVR) and rapid ascension of transcatheter mitral and tricuspid therapies.

TVT, the Structural Heart Summit, now in its twelfth year, is designed for a multidisciplinary audience of clinical practitioners, healthcare professionals, academicians, engineers, and scientists – including clinical cardiologists, cardiac imaging specialists (especially echo and CT), cardiac and vascular surgeons, electrophysiologists, heart failure specialists, nurse practitioners and physician assistants, cath lab technicians, other healthcare professionals, and members of the medical device community who are interested in valvular and structural heart disease.

TVT will provide a comprehensive review of the best clinical practices in the management of valvular and structural heart disease (including LAA and PFO closure therapies), including in-depth coverage of less invasive transcatheter devices currently in clinical use or under investigation.